Previous close | 0.6176 |
Open | 0.6268 |
Bid | 0.6500 x 900 |
Ask | 0.6990 x 1400 |
Day's range | 0.5550 - 0.6268 |
52-week range | 0.3650 - 1.5000 |
Volume | |
Avg. volume | 487,809 |
Market cap | 5.202M |
Beta (5Y monthly) | 1.27 |
PE ratio (TTM) | 0.34 |
EPS (TTM) | 1.7700 |
Earnings date | 28 Mar 2024 - 29 Mar 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
CHICAGO, February 05, 2024--Exicure, Inc., (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company focused on viral and liver diseases, announced today that Bluejay Therapeutics, Inc. ("Bluejay") and Exicure, Inc. ("Exicure") entered into a patent license agreement to develop cavrotolimod for potential treatment for hepatitis.
CHICAGO, November 28, 2023--Exicure, Inc. ("Exicure" or the "Company") (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on November 22, 2023 notifying the Company that, as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 (the "Form 10-Q"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies
Exicure, Inc. ( NASDAQ:XCUR ) shares have had a horrible month, losing 25% after a relatively good period beforehand...